Cisplatin and Gemcitabine

Small molecule

NNational University Hospital, Singapore

Cisplatin and Gemcitabine is one of 72 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Intrahepatic CholangiocarcinomaPhase 2/Phase 3

Active, not recruiting

Triple-Negative Breast CancerPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

249 competitors in Triple-Negative Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

30 2

Abraxane

Bristol-Myers Squibb

Phase 3

23 3

Halaven

Eisai

Phase 3

12 4

Gemzar

Johnson & Johnson

Phase 3

10 5

Halaven

Eisai

Phase 3

3 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

13 7

Xtandi

Astellas

Phase 3

2 8

Tuoyi

SSun Yat-sen University

Phase 3

5 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 10

Cosela

PPharmacosmos A/S

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2/3Not yet recruiting

Triple-Negative Breast Cancer

NCT06268327

Phase 2Recruiting

Nasopharyngeal Cancer

NCT05305131

Clinical

Trials by Indication[1]

Nasopharyngeal Cancer1 trial

Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer

Recruiting·NNational University Hospital, Singapore·Phase 2·NCT05305131·50 enrolled

Gemcitabine1 trial

Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.

Completed·UUniversity of Zurich·Phase 1/2·NCT01073839·33 enrolled

Triple-Negative Breast Cancer1 trial

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

Not yet recruiting·—·Phase 2/3·NCT06268327·30 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Unknown status·DDelcath Systems Inc.·Phase 2/3·NCT03086993·295 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Cisplatin and Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cisplatin and Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cisplatin and Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National University Hospital, Singapore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNational University Hospital, Singapore

Cisplatin and Gemcitabine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Nasopharyngeal Cancer1 trial

Gemcitabine1 trial

Triple-Negative Breast Cancer1 trial

Intrahepatic Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News